Cardiac resynchronization therapy (CRT) has been first reported more than 10 years ago as a therapy for patients with severe chronic heart failure. The efficacy of CRT has been proven in many studies that it improves not only quality of life but also the prognosis of the patients. Its indication has been expanded for patients with mild heart failure. On the other hand, some patients cannot receive enough benefit through CRT.
It is also important to prevent sudden cardiac death due to lethal arrhythmias in HF patients, and CRT with defibrillators (CRT-D) has been applied in most cases. The indication for CRT or CRT-D is decided based on the guideline on nonpharmacotherapy for arrhythmias by Japanese Circulation Society and Japanese Heart Rhythm Society published in 2011. 5 However, many clinical studies have been demonstrating new evidences on CRT every year and we need to keep up the latest evidences to provide best treatment for the patients. 6, 7 This review article describes on the history, advancement, indication, current limitations, and the future of CRT. To recognize the position of CRT as one of the established treatments for HF is important for the doctors who are involved in primary care medicine to foresee the treatments which should be provided for the patients with HF. Cardiologists were used to place a catheter and pace in the coronary sinus (CS) and got an idea to place a pacing lead in a branch of CS instead of pacing the left ventricle using an endocardial lead which has a risk of arterial thromboembolism. As shown in Figure 2 , three leads are usually placed in the heart transvenously; one in the right atrium, 
| IMPROVEMENT OF SURVIVAL AS WELL AS QOL
Many
| EXPANDING INDICATION FOR CRT
How much we can expand the indication of CRT was the next issue.
One of the targets was HF patients with mild symptom. REVERSE trial 10 published in 2008 enrolled patients with NYHA class I and II heart failure patients, QRS width ≥120 ms, EF ≤40% and revealed that CRT not only prevented the re-admission due to heart failure but brought remodeling of cardiac dilatation and improved EF of LV. Also, 
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Before CRT After CRT F I G U R E 2 Chest x-ray after implantation of defibrillator with cardiac resynchronization therapy (CRT-D). Three leads are placed in the heart transvenously. Left ventricular lead is placed in the coronary sinus branch
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I or II heart failure and proved the efficacy of CRT-D in this patient group. RAFT trial 12 which enrolled NYHA class II or III heart failure patients showed no statistical difference on the effect of CRT between NYHA classes and established the efficacy of CRT in patients with early stage HF. As shown in Table 1 and Table 2 , the current Japanese indications of CRT or CRT-D are based on the nonpharmacotherapy of arrhythmia by Japanese Society of Cardiology revised in 2011.
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Although the indications for NYHA class II heart failure patients are partially indicated in this guideline, the indications of CRT therapy will expand furthermore in the future based on the recent evidences.
| CAN WE PREDICT THE EFFECT OF CRT?
Despite the expanding indication of CRT for patients with CHF, 
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On the other hand, we had been still anticipating that the patient with dyssynchrony on echo cardiography can get benefit from CRT even if QRS width is not wide enough. However, EchoCRT study 17 which enrolled patients with NYHA class III or IV heart failure patients who presented QRS <130 ms but presented apparent dyssynchrony on echocardiography resulted in presenting no benefit of CRT. To consider indications of CRT, careful discussion based on evidence is important.
| HOW TO REDUCE NONRESPONDER? IMPORTANCE OF APPROPRIATE LV PACING SITE
Patients with heart failure often accompany with atrial fibrillation, which makes bi-ventricular pacing difficult due to increased intrinsic T A B L E 1 Indication of CRT Pacemaker (CRT-P) from JCS Guideline 2011 (Ref.
)
Class I:
1. CRT-P is recommended in chronic HF patients with LVEF ≤35%, QRS duration ≥120 ms, in sinus rhythm who remain in NYHA functional class III and ambulatory IV despite adequate medical treatment.
Class IIa:
1. CRT-P should be considered in chronic HF patients with LVEF ≤35%, QRS duration ≥120 ms, with atrial fibrillation who remain in NYHA functional class III and ambulatory IV despite adequate medical treatment.
2. CRT-P should be considered in chronic HF patients with LVEF ≤35% who remain in NYHA functional class III and ambulatory IV despite adequate medical treatment and when a pacemaker has been already implanted or planned to be implanted and also when frequent ventricular pacing is expected.
Class IIb:
1. CRT-P may be considered in chronic HF patients with LVEF ≤35% who remain in NYHA functional class II despite adequate medical treatment and when a pacemaker has been planned to be implanted and also when frequent ventricular pacing is expected.
Class III:
1. CRT-P is not indicated in asymptomatic patients with reduced LVEF and when pacemaker is not indicated.
2. CRT-P is not indicated in patients whose physical activity is limited due to chronic diseases other than heart failure or when life expectancy ≥ 12 mo is not expected.
T A B L E 2 Indication of CRT with defibrillator (CRT-D) from JCS
Guideline 2011 (Ref.
)
1. CRT-D is recommended in chronic HF patients with LVEF ≤35%, QRS duration ≥120 ms, in sinus rhythm who remain in NYHA functional class III and ambulatory IV despite adequate medical treatment and when ICD is also indicated.
1. CRT-D should be considered in chronic HF patients with LVEF ≤35%, QRS duration ≥120 ms, with atrial fibrillation who remain in NYHA functional class III and ambulatory IV despite adequate medical treatment and when ICD is also indicated.
2. CRT-D should be considered in chronic HF patients with LVEF ≤30%, QRS duration ≥150 ms, in sinus rhythm who remain in NYHA functional class II despite adequate medical treatment and when ICD is also indicated.
3. CRT-D should be considered in chronic HF patients with LVEF ≤35% who remain in NYHA functional class III and ambulatory IV despite adequate medical treatment and when an ICD has been already implanted or planned to be implanted and also when the patient is dependent on ventricular pacing or frequent ventricular pacing is expected.
1. CRT-D may be considered in chronic HF patients with LVEF ≤35% who remain in NYHA functional class II despite adequate medical treatment and when an ICD has been planned to be implanted and also when frequent ventricular pacing is expected.
1. CRT-D is not indicated in asymptomatic patients with reduced LVEF and when ICD is not indicated.
2. CRT-D is not indicated in patients whose physical activity is limited due to chronic diseases other than heart failure or when life expectancy ≥ 12 mo is not expected.
heart rate. Although the efficacy of CRT in patients with atrial fibrillation has been reported, it is important to inhibit intrinsic heart rate by beta-blocker or ablation of atrioventricular node, otherwise the benefit of CRT cannot be fully utilized. On the other hand, we need to think about the cost of CRT-Ds.
Although ICD can prevent sudden cardiac death due to lethal arrhythmia, heart failure has been the majority of causes of death in patients receiving CRT-Ds. It is reported that when compared with CRT-D patients, excess mortality in CRT pacemaker recipients was mainly due to nonsudden death. [29] [30] [31] It is the time to consider how to select patients who should be treated with a defibrillator and who should be treated with a pacemaker.
| CONCLUSION
CRT is one of the established treatments of CHF supported by enough evidences and brings huge benefit for the patients when accompanied with adequate pharmacotherapy, cardiac rehabilitation, patient education, and so on. Patients with NYHA class II or III heart failure who present reduced EF ≤35%, QRS >150 m with left bundle branch block are likely to well respond to this therapy. On the other hand, we need to discuss on the indication of CRT for patients with narrow QRS considering the nonresponder rate and adverse effect of CRT. Appropriate understanding of this therapy by the doctors who are involved in primary care medicine is important because it is critical to introduce CRT for adequate patients in good timing.
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F I G U R E 3 Quadripolar left ventricular lead. This lead is useful to avoid apical pacing and can change the pacing site noninvasively when phrenic nerve stimulation is observed Quadri-polar left ventricular lead
